Drug Pricing: Overview
- Overview of Drug Pricing for Public Programs (PDF) (April 2010)
From Project Inform
- The Price Isn't Right (January 25, 2008)
BMS raises HIV/AIDS drug prices, refuses to engage with treatment activists.
In Housing Works AIDS Issues Update, from Housing Works
- Untangling the Economics of Drug Pricing (May 2004)
Transcript and slides of a talk by Joshua P. Cohen, a senior research fellow at the Tufts Center for the Study of Drug Development.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- An Overview of AIDS Drug Access in the United States (May 2004)
Transcript of a talk by Christine Lubinski, Executive Director of the HIV Medicine Association.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Defining the Impact of AIDS Drug Pricing on the Private Sector (May 2004)
Transcript and slides of a talk by Michael Allerton, HIV Operations Policy Coordinator at the Permanente Medical Group.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Defining the Impact of AIDS Drug Pricing on the Public Sector (May 2004)
Transcript and slides of a talk by Lanny Cross, Program Manager of the New York State AIDS Drug Assistance Program.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations (April 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Patient Care Squeezed by Soaring Drug Prices (April 2002)
An in-depth examination of the drug-pricing war raging in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Pricing: News & Analysis
- AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild (February 1, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Generic HIV Drugs Will Widen U.S. Treatment Net (August 24, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Warned by Democrats Over "Quad" Pricing (August 17, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Generic-Based Regimen in U.S. Could Save Nearly $1 Billion in First Year of Use (August 14, 2012)
From AIDSmeds.com
- Reducing Commodity Costs for ARVs Could Mean Providing Treatment to Millions More People (August 2, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Global Health Partnership Announces First-, Second-Line AIDS Drugs Price Reductions in Developing World (May 18, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- Bloomberg BusinessWeek Explores Growing Trend in Pharma to License, Donate HIV Drugs (August 6, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Can More People Be Put on ART Without Increased Cost? (Summer 2010)
To read PDF, click here.
In TAGline, from Treatment Action Group
VIEW ALL ARTICLES
The Ritonavir (Norvir) Price Increase
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Why Abbott Is Allowed to Manipulate GSK and BMS's AIDS Drug Prices (July 8, 2009)
From BNET
- Federal Appeals Court Rejects Lawsuit Against Abbott Laboratories Over Ritonavir Price Hike (July 7, 2009)
Abbott Laboratories was not taking advantage of its monopoly on antiretroviral boosters to unfairly raise the price of ritonavir (Norvir), a U.S. federal appeals court has ruled.
From Bloomberg.com
- Abbott Agrees to Settle Lawsuit Over Norvir Price Hike (August 1, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- GSK Joins Lawsuit Against Abbott Over Price of Ritonavir (November 12, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Pharmacies, Drug Wholesaler File Lawsuit Against Abbott Over Ritonavir Price (October 30, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Wall Street Journal Examines Reason Abbott Increased Price of Antiretroviral Norvir (January 3, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aetna Files Lawsuit Against Abbott Over 400% Price Increase of Ritonavir (May 27, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- U.S. Government Holds Hearing on Generic Production of Ritonavir (May 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abbott's Norvir Price Hike Is Bad Medicine (May/June 2004)
Bob Huff explains why the December 2003 ritonavir price increase may well doom the development of boosted protease inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Two HIV-Infected Patients File U.S. Antitrust Suit Against Ritonavir Price Hike (April 20, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Hearing on Drug Reimportation to Include Discussion of Abbott's Pricing of Antiretroviral Norvir (April 14, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Viewpoints
Email
